About Delcath Systems (OTCMKTS:DCTHD)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Industry, Sector and Symbol
Industry Medical Prosthetics
Trailing P/E Ratio-6.5255104633185E-05
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$1.99 million
Price / Sales0.12
Price / CashN/A
Book Value($0.71) per share
Price / Book-0.13
Return on Equity-3,960.73%
Return on Assets-165.16%
Delcath Systems (OTCMKTS:DCTHD) Frequently Asked Questions
What is Delcath Systems' stock symbol?
Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTHD."
When did Delcath Systems' stock split? How did Delcath Systems' stock split work?
Shares of Delcath Systems reverse split on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 0 shares after the split.
How were Delcath Systems' earnings last quarter?
Delcath Systems, Inc. (OTCMKTS:DCTHD) issued its quarterly earnings data on Friday, November, 11th. The medical device company reported ($231.00) EPS for the quarter, beating the Zacks' consensus estimate of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. Delcath Systems had a negative net margin of 1,278.64% and a negative return on equity of 3,960.73%. During the same period last year, the firm earned ($686.00) earnings per share. View Delcath Systems' Earnings History.
Who are some of Delcath Systems' key competitors?
Some companies that are related to Delcath Systems include Neovasc Inc (US) (NVCN), Eyegate Pharmaceuticals (EYEG), Neurometrix (NURO), Windtree Therapeutics (WINT), SenesTech (SNES), Alliqua Biomedical (ALQA), Auris Medical (EARS), Anthera Pharmaceuticals (ANTH), Bioblast Pharma (ORPN), Argos Therapeutics (ARGS), Sunshine Heart (CHFS), Precipio (PRPO), Immune Pharmaceuticals (IMNP), Mateon Therapeutics (MATN), Cotinga Pharmaceut (COTQF), Secure Point Technologies (IMSC), Strata Skin Sciences (SSKN) and Amedica (AMDA).
Who are Delcath Systems' key executives?
Delcath Systems' management team includes the folowing people:
- Roger G. Stoll Ph.D., Chairman of the Board (Age 74)
- Jennifer K. Simpson Ph.D., President, Chief Executive Officer, Director (Age 48)
- Barbra C. Keck, Chief Financial Officer, Secretary (Age 39)
- John Purpura, Executive Vice President - Global Head of Operations (Age 55)
- Simon C. Pedder Ph.D., Director (Age 56)
- William Dodge Rueckert, Independent Director (Age 64)
- Marco Taglietti M.D., Independent Director (Age 57)
Has Delcath Systems been receiving favorable news coverage?
Headlines about DCTHD stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Delcath Systems earned a media sentiment score of 0.17 on Accern's scale. They also assigned news headlines about the medical device company an impact score of 45.34 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Delcath Systems?
Shares of DCTHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Delcath Systems' stock price today?
One share of DCTHD stock can currently be purchased for approximately $0.09.
How big of a company is Delcath Systems?
Delcath Systems has a market capitalization of $5.48 million and generates $1.99 million in revenue each year. The medical device company earns $-17,970,000.00 in net income (profit) each year or ($1,377.67) on an earnings per share basis. Delcath Systems employs 43 workers across the globe.
How can I contact Delcath Systems?
Delcath Systems' mailing address is 1633 Broadway Ste 22C, NEW YORK, NY 10019-6708, United States. The medical device company can be reached via phone at +1-212-4892100 or via email at [email protected]
MarketBeat Community Rating for Delcath Systems (DCTHD)MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Delcath Systems (OTCMKTS:DCTHD) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Delcath Systems (OTCMKTS:DCTHD) Earnings History and Estimates Chart
Delcath Systems (OTCMKTS DCTHD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/11/2016||Q3 2016||($1,151.50)||($231.00)||$0.44 million||View||N/A|
|8/16/2016||Q2||($1,543.50)||$466.00 million||$511.00 million||View||N/A|
|8/5/2015||Q2||($105.00)||$251.00 million||$466.00 million||View||N/A|
|5/7/2014||Q114||($224.00)||($199.50)||$0.20 million||$0.31 million||View||Listen|
|3/12/2014||Q413||($17.50)||($14.00)||$0.10 million||$0.30 million||View||Listen|
|11/6/2013||Q313||($28.00)||($24.50)||$0.30 million||$0.07 million||View||Listen|
|8/6/2013||Q2 2013||($38.50)||($21.00)||$0.30 million||View||Listen|
|5/8/2013||Q1 2013||($45.50)||($52.50)||$0.28 million||$0.30 million||View||Listen|
Delcath Systems (OTCMKTS:DCTHD) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Delcath Systems (OTCMKTS:DCTHD)
No dividend announcements for this company have been tracked by MarketBeat.com
Delcath Systems (OTCMKTS DCTHD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.03%
Delcath Systems (OTCMKTS DCTHD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/23/2015||Laura A Philips||Director||Buy||162,653||$0.50||$81,326.50|| |
|7/22/2015||William Dodge Rueckert||Director||Buy||20,000||$0.48||$9,600.00|| |
Delcath Systems (OTCMKTS DCTHD) News Headlines
Delcath Systems (OTCMKTS:DCTHD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Delcath Systems (OTCMKTS DCTHD) Stock Chart for Tuesday, March, 20, 2018